Purpose To describe the long-term outcomes of intravitreal bevacizumab (IVB) for the
treatment of pediatric retinal and choroidal diseases. Methods This was a multicenter,
retrospective, consecutive case series of patients< 18 years of age treated with IVB from
2005 to 2013. Primary outcome measures included visual acuity and central macular
thickness at 12 months' follow-up. Results A total of 95 eyes of 90 patients (average age, 8.7
years [range, 0.33-17 years]) were included, in which 352 injections (average, 3.7/eye) were …